Our Science

Molecular Design Meets Material Science

At Ripple, we discovered that with a small amount of chemical engineering, drugs can be transformed into implantable prodrug materials.

These remarkable materials undergo surface erosion which results in release of the active drug.

By tuning surface area and implant geometry, drug dose and duration can be precisely designed to meet the therapeutic need.

The proprietary Epidel® prodrugs have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices.

Engineering drugs that deliver themselves

Drug dissolves from the surface of the Epidel implant via surface erosion in a highly predictable manner: dose is dictated by implant surface area; dose duration by implant diameter.

The result is an ability to finely tune pharmacokinetics to meet the needs of a target indication with precision control of drug dosing without the bulk added by a polymer.

Pipeline

Ripple Therapeutics ophthalmology pipeline addresses multiple $1B+ market opportunities

IBE-814 IVT dexamethasone releasing implant

IBE-814 IVT is aimed at being best-in-class treatment of posterior inflammatory eye diseases, including diabetic macular edema (DME), retinal vein occlusion (RVO) and non-infectious uveitis (NIU).